Abstract:Site-specific genetic and epigenetic targeting of distinct cell populations is a central goal in molecular neuroscience and is crucial to understand the gene regulatory mechanisms that underlie complex phenotypes and behaviors. While recent technological advances have enabled unprecedented control over gene expression, many of these approaches are focused on selected model organisms and/or require labor-intensive customization for different applications. The simplicity and modularity of clustered regularly interspaced short palindromic repeats (CRISPR)-based systems have transformed genome editing and expanded the gene regulatory toolbox. However, there are few available tools for cell-selective CRISPR regulation in neurons. We designed, validated, and optimized CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi) systems for Cre recombinase-dependent gene regulation. Unexpectedly, CRISPRa systems based on a traditional double-floxed inverted open reading frame (DIO) strategy exhibited leaky target gene induction even without Cre. Therefore, we developed an intron-containing Cre-dependent CRISPRa system (SVI-DIO-dCas9-VPR) that alleviated leaky gene induction and outperformed the traditional DIO system at endogenous genes in HEK293T cells and rat primary neuron cultures. Using gene-specific CRISPR sgRNAs, we demonstrate that SVI-DIO-dCas9-VPR can activate numerous rat or human genes ( GRM2 , Tent5b , Fos , Sstr2 , and Gadd45b ) in a Cre-specific manner. To illustrate the versatility of this tool, we created a parallel CRISPRi construct that successfully inhibited expression from a luciferase reporter in HEK293T cells only in the presence of Cre. These results provide a robust framework for Cre-dependent CRISPR-dCas9 approaches across different model systems, and enable cell-specific targeting when combined with common Cre driver lines or Cre delivery via viral vectors.

Targeted gene silencing in the nervous system with CRISPR-Cas13

CRISPR interference-based specific and efficient gene inactivation in the brain

An Improved CRISPR/dCas9 Interference Tool for Neuronal Gene Suppression

CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes

An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models

CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

A Cre-Dependent CRISPR/dCas9 System for Gene Expression Regulation in Neurons

A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation

Characterisation of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina

Alleviation of neurological disease by RNA editing

Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins

Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice

RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors

Tunable, self-contained gene dosage control via proteolytic cleavage of CRISPR-Cas systems

The Bacterial Enzyme RfxCas13d Is Less Neurotoxic Than PspCas13b and Could Be a Promising RNA Editing and Interference Tool in the Nervous System

In Situ Gene Therapy Via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.

Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing

CRISPR/Cas9-mediated Gene Editing Ameliorates Neurotoxicity in Mouse Model of Huntington’s Disease

Silencing of the Mutant Huntingtin Gene through CRISPR-Cas9 Improves the Mitochondrial Biomarkers in an In Vitro Model of Huntington’s Disease

Precise CAG repeat contraction in a Huntington’s Disease mouse model is enabled by gene editing with SpCas9-NG